The dysplastic nevus: From historical perspective to management in the modern era: Part II. Molecular aspects and clinical management

Journal of the American Academy of Dermatology

Volumn 67, Issue 1, 2012, Pages 19.e1-19.e12

  Duffy, Keith ^a   Grossman, Douglas ^a,b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

common nevus; dysplasia; dysplastic nevus; melanoma; nevus

Indexed keywords

B RAF KINASE; FLUOROURACIL; HYDROCORTISONE; IMIQUIMOD; ISOTRETINOIN; PROTEIN P16; REACTIVE OXYGEN METABOLITE; RETINOIC ACID;

ALLELE; APOPTOSIS; CANCER RISK; CLONAL VARIATION; CONGENITAL NEVUS; CONTINUING EDUCATION; DERMATOLOGIST; DYSPLASTIC NEVUS; GENE EXPRESSION; GENE MUTATION; HEALTH CARE PERSONNEL; HETEROZYGOSITY LOSS; HUMAN; LASER SURGERY; MALIGNANT TRANSFORMATION; MEDICAL EDUCATION; MEDICAL LITERATURE; MELANOMA; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSIS; OXIDATIVE STRESS; PATIENT CARE; PEER REVIEW; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SENESCENCE;

EID: 84862303996     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.03.013     Document Type: Review

References (101)

1. W.H. Clark Jr., R.R. Reimer, M. Greene, A.M. Ainsworth, and M.J. Mastrangelo Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome' Arch Dermatol 114 1978 732 738
2. L.J. Klein, and R.J. Barr Histologic atypia in clinically benign nevi. A prospective study J Am Acad Dermatol 22 1990 275 282 (Pubitemid 20209102)
3. G. Annessi, M.S. Cattaruzza, D. Abeni, G. Baliva, M. Laurenza, and V. Macchini Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi J Am Acad Dermatol 45 2001 77 85 (Pubitemid 32655699)
4. M.A. Tucker, A. Halpern, E.A. Holly, P. Hartge, D.E. Elder, and R.W. Sagebiel Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma JAMA 277 1997 1439 1444 (Pubitemid 27208885)
5. J.W. Kelly, J.M. Yeatman, C. Regalia, G. Mason, and A.P. Henham A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance Med J Aust 167 1997 191 194 (Pubitemid 27387245)
6. NIH Consensus conference Diagnosis and treatment of early melanoma JAMA 268 1992 1314 1319
7. A.W. Kopf What is early melanoma? Am J Dermatopathol 15 1993 44 45 (Pubitemid 23057422)
8. A.B. Ackerman A critique of an N.I.H. Consensus Development Conference about "early" melanoma Am J Dermatopathol 15 1993 52 58
9. E.J. Glusac What to call the LEJC-BFV nevus? J Cutan Pathol 31 2004 521 522 (Pubitemid 39061799)
10. S.F. Cramer War and peace in the realm of dysplastic nevi J Cutan Pathol 32 2005 319 320 (Pubitemid 40459938)
11. M.A. Hurt The melanocytic nevus described by Clark et al. What is its nature? What should it be named? An answer from history and from logic J Cutan Pathol 32 2005 457 460 (Pubitemid 41039394)
12. J.M. Tripp, A.W. Kopf, A.A. Marghoob, and R.S. Bart Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology J Am Acad Dermatol 46 2002 674 682
13. D.V. Yonick, R.M. Ballo, E. Kahn, M. Dahiya, K. Yao, and C. Godellas Predictors of positive sentinel lymph node in thin melanoma Am J Surg 201 2011 324 327
14. G.V. Wettengel, J. Draeger, F. Kiesewetter, H. Schell, S. Neubauer, and E. Gebhart Differentiation between Spitz nevi and malignant melanomas by interphase fluorescence in situ hybridization Int J Oncol 14 1999 1177 1183
15. B.C. Bastian, P.E. LeBoit, and D. Pinkel Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features Am J Pathol 157 2000 967 972 (Pubitemid 32109388)
16. P. Gerami, A. Wass, M. Mafee, Y. Fang, M.P. Pulitzer, and K.J. Busam Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi Am J Surg Pathol 33 2009 1783 1788
17. W.A. Robinson, M. Lemon, A. Elefanty, M. Harrison-Smith, N. Markham, and D. Norris Human acquired naevi are clonal Melanoma Res 8 1998 499 503 (Pubitemid 29046500)
18. R.J. Barr, K.G. Linden, G. Rubinstein, and K.A. Cantos Analysis of heterogeneity of atypia within melanocytic nevi Arch Dermatol 139 2003 289 292 (Pubitemid 36330575)
19. M. Scatolini, M.M. Grand, E. Grosso, T. Venesio, A. Pisacane, and A. Balsamo Altered molecular pathways in melanocytic lesions Int J Cancer 126 2010 1869 1881
20. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954 (Pubitemid 34716871)
21. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
22. P.M. Pollock, U.L. Harper, K.S. Hansen, L.M. Yudt, M. Stark, and C.M. Robbins High frequency of BRAF mutations in nevi Nat Genet 33 2003 19 20 (Pubitemid 36068675)
23. J. Wu, E. Rosenbaum, S. Begum, and W.H. Westra Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis Am J Dermatopathol 29 2007 534 537 (Pubitemid 350158863)
24. P. Uribe, L. Andrade, and S. Gonzalez Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi J Invest Dermatol 126 2006 161 166 (Pubitemid 43336108)
25. J. Bauer, J.A. Curtin, D. Pinkel, and B.C. Bastian Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations J Invest Dermatol 127 2007 179 182 (Pubitemid 46005676)
26. T. Papp, H. Pemsel, I. Rollwitz, H. Schipper, D.G. Weiss, and D. Schiffmann Mutational analysis of N-ras, p53, CDKN2A (p16(INK4a)), p14(ARF), CDK4, and MC1R genes in human dysplastic melanocytic naevi J Med Genet 40 2003 E14
27. T. Papp, H. Schipper, K. Kumar, D. Schiffmann, and R. Zimmermann Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi Melanoma Res 15 2005 401 407 (Pubitemid 41558950)
28. C.J. Sherr Cancer cell cycles Science 274 1996 1672 1677
29. V.C. Gray-Schopfer, S.C. Cheong, H. Chong, J. Chow, T. Moss, and Z.A. Abdel-Malek Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 95 2006 496 505 (Pubitemid 44232559)
30. M.A. Tucker, M.C. Fraser, A.M. Goldstein, J.P. Struewing, M.A. King, and J.T. Crawford A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families Cancer 94 2002 3192 3209 (Pubitemid 34670503)
31. H. Wang, R.B. Presland, and M. Piepkorn A search for CDKN2A/p16INK4a mutations in melanocytic nevi from patients with melanoma and spouse controls by use of laser-captured microdissection Arch Dermatol 141 2005 177 180 (Pubitemid 40216259)
32. J.Y. Lee, S.M. Dong, M.S. Shin, S.Y. Kim, S.H. Lee, and S.J. Kang Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus Biochem Biophys Res Commun 237 1997 667 672 (Pubitemid 27434745)
33. D.E. Brash, J.A. Rudolph, J.A. Simon, A. Lin, G.J. McKenna, and H.P. Baden A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma Proc Natl Acad Sci U S A 88 1991 10124 10128 (Pubitemid 21915787)
34. C.L. Benjamin, V.O. Melnikova, and H.N. Ananthaswamy P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer Adv Exp Med Biol 624 2008 265 282
35. D.B. Levin, and K. Wilson Valadares de Amorim G, Webber J, Kenny P, Kusser W. Detection of p53 mutations in benign and dysplastic nevi Cancer Res 55 1995 4278 4282
36. N.J. Lassam, L. From, and H.J. Kahn Overexpression of p53 is a late event in the development of malignant melanoma Cancer Res 53 1993 2235 2238 (Pubitemid 23156806)
37. J.M. Radhi Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components J Cutan Med Surg 3 1999 293 297 (Pubitemid 29467298)
38. J.M. McGregor, C.C. Yu, E.A. Dublin, D.M. Barnes, D.A. Levison, and D.M. MacDonald p53 immunoreactivity in human malignant melanoma and dysplastic naevi Br J Dermatol 128 1993 606 611 (Pubitemid 23172016)
39. T. Batinac, I. Hadzisejdic, G. Brumini, A. Ruzic, B. Vojnikovic, and G. Zamolo Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions Coll Antropol 31 suppl 1 2007 17 22
40. M. Keniry, and R. Parsons The role of PTEN signaling perturbations in cancer and in targeted therapy Oncogene 27 2008 5477 5485
41. H. Tsao, M.C. Mihm Jr., and C. Sheehan PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma J Am Acad Dermatol 49 2003 865 872 (Pubitemid 37314875)
42. R.S. Singh, A.H. Diwan, P.S. Zhang, and V.G. Prieto Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions J Cutan Pathol 34 2007 220 225 (Pubitemid 46239310)
43. M.R. Hussein, M. Sun, R.J. Tuthill, E. Roggero, J.A. Monti, and E.C. Sudilovsky Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi J Cutan Pathol 28 2001 343 350 (Pubitemid 32667004)
44. R. Boni, Z. Zhuang, A. Albuquerque, A. Vortmeyer, and P. Duray Loss of heterozygosity detected on 1p and 9q in microdissected atypical nevi Arch Dermatol 134 1998 882 883 (Pubitemid 28350203)
45. S.J. Bale, N.C. Dracopoli, M.A. Tucker, W.H. Clark Jr., M.C. Fraser, and B.Z. Stanger Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p N Engl J Med 320 1989 1367 1372 (Pubitemid 19138930)
46. A.M. Goldstein, N.C. Dracopoli, E.C. Ho, M.C. Fraser, K.S. Kearns, and S.J. Bale Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity Am J Hum Genet 52 1993 537 550 (Pubitemid 23311324)
47. A.M. Goldstein, L.R. Goldin, N.C. Dracopoli, W.H. Clark Jr., and M.A. Tucker Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi Am J Hum Genet 58 1996 1050 1056 (Pubitemid 26115177)
48. M. Falchi, V. Bataille, N.K. Hayward, D.L. Duffy, J.A. Bishop, and T. Pastinen Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi Nat Genet 41 2009 915 919
49. S. Birindelli, G. Tragni, C. Bartoli, G.N. Ranzani, F. Rilke, and M.A. Pierotti Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma Int J Cancer 86 2000 255 261 (Pubitemid 30180822)
50. T.P. Tran, L. Titus-Ernstoff, A.E. Perry, M.S. Ernstoff, and I.F. Newsham Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression Cancer Causes Control 13 2002 675 682 (Pubitemid 35001775)
51. W.S. Park, A.O. Vortmeyer, S. Pack, P.H. Duray, R. Böni, and A.A. Guerami Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus Hum Pathol 29 1998 127 130 (Pubitemid 28099506)
52. M.C. Sini, A. Manca, A. Cossu, M. Budroni, G. Botti, and P.A. Ascierto Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma Br J Dermatol 158 2008 243 250
53. R. Keller-Melchior, R. Schmidt, and M. Piepkorn Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions J Invest Dermatol 110 1998 932 938 (Pubitemid 28237700)
54. J.M. Grichnik Dermoscopy of melanocytic neoplasms: subpatterns of dysplastic/atypical nevi Arch Dermatol 140 2004 142
55. B. Lebe, U. Pabuccuoglu, and E. Ozer The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions Appl Immunohistochem Mol Morphol 15 2007 160 164 (Pubitemid 46828222)
56. A. Alekseenko, A. Wojas-Pelc, G.J. Lis, A. Furgal-Borzych, G. Surowka, and J.A. Litwin Cyclin D1 and D3 expression in melanocytic skin lesions Arch Dermatol Res 302 2010 545 550
57. M.R. Nasr, and O. El-Zammar Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions Am J Dermatopathol 30 2008 117 122 (Pubitemid 351441982)
58. T. Alanko, M. Rosenberg, and O. Saksela FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes J Invest Dermatol 113 1999 111 116 (Pubitemid 29328168)
59. C.R. Morales-Ducret, M. van de Rijn, and B.R. Smoller bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation Arch Dermatol 131 1995 915 918
60. V.A. Tron, S. Krajewski, H. Klein-Parker, G. Li, V.C. Ho, and J.C. Reed Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma Am J Pathol 146 1995 643 650
61. D. Grossman, J.M. McNiff, F. Li, and D.C. Altieri Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma J Invest Dermatol 113 1999 1076 1081 (Pubitemid 30013356)
62. S.R. Florell, A.R. Bowen, A.N. Hanks, K.J. Murphy, and D. Grossman Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi J Cutan Pathol 32 2005 45 49 (Pubitemid 40174105)
63. L. Zhuang, C.S. Lee, R.A. Scolyer, S.W. McCarthy, X.D. Zhang, and J.F. Thompson Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand Hum Pathol 37 2006 1286 1294 (Pubitemid 44380273)
64. Z. Zhang, G. Chen, Y. Cheng, M. Martinka, and G. Li Prognostic significance of RUNX3 expression in human melanoma Cancer 117 2011 2719 2727
65. S. Pavel, F. van Nieuwpoort, H. van der Meulen, C. Out, K. Pizinger, and P. Cetkovská Disturbed melanin synthesis and chronic oxidative stress in dysplastic naevi Eur J Cancer 40 2004 1423 1430 (Pubitemid 38737030)
66. N.P. Smit, F.A. van Nieuwpoort, L. Marrot, C. Out, B. Poorthuis, and H. van Pelt Increased melanogenesis is a risk factor for oxidative DNA damage - study on cultured melanocytes and atypical nevus cells Photochem Photobiol 84 2008 550 555 (Pubitemid 351589354)
67. W.J. Mooi, and D.S. Peeper Oncogene-induced cell senescence - halting on the road to cancer N Engl J Med 355 2006 1037 1046 (Pubitemid 44343547)
68. C.Y. Dai, and G.H. Enders p16 INK4a can initiate an autonomous senescence program Oncogene 19 2000 1613 1622 (Pubitemid 30200963)
69. C. Michaloglou, L.C. Vredeveld, M.S. Soengas, C. Denoyelle, T. Kuilman, and C.M. van der Horst BRAFE600-associated senescence-like cell cycle arrest of human naevi Nature 436 2005 720 724 (Pubitemid 41117276)
70. M.A. Cotter, S.R. Florell, S.A. Leachman, and D. Grossman Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo J Invest Dermatol 127 2007 2469 2471 (Pubitemid 47619764)
71. V.C. Gray-Schopfer, J.K. Soo, and D.C. Bennett Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo" J Invest Dermatol 128 2008 1581 (Pubitemid 351693206)
72. C. Michaloglou, M.S. Soengas, W.J. Mooi, and D.S. Peeper Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo" J Invest Dermatol 128 2008 1582 1583 (Pubitemid 351693207)
73. M.A. Cotter, S.R. Florell, S.A. Leachman, and D. Grossman Reply to responses to "Absence of senescence-associated β-galactosidase activity in human melanocytic nevi in vivo" J Invest Dermatol 128 2008 1583 1584
74. D.C. Bennett Human melanocyte senescence and melanoma susceptibility genes Oncogene 22 2003 3063 3069 (Pubitemid 36713756)
75. N. Wajapeyee, R.W. Serra, X. Zhu, M. Mahalingam, and M.R. Green Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7 Cell 132 2008 363 374 (Pubitemid 351191995)
76. N. Wajapeyee, R.W. Serra, X. Zhu, M. Mahalingam, and M.R. Green Role for IGFBP7 in senescence induction by BRAF Cell 141 2010 746 747
77. K. Decarlo, S. Yang, A. Emley, N. Wajapeyee, M. Green, and M. Mahalingam Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7 - challenging the concept of dysplastic nevi as precursor lesions? Hum Pathol 41 2010 886 894
78. L.P. Nguyen, A. Emley, N. Wajapeyee, M.R. Green, and M. Mahalingam BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi Br J Dermatol 162 2010 677 680
79. National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992 Am J Dermatopathol 15 1993 34 43
80. A.G. Goodson, and D. Grossman Strategies for early melanoma detection: approaches to the patient with nevi J Am Acad Dermatol 60 2009 719 735
81. J. Vink, M.B. Crijns, C.M. Mooy, W. Bergman, J.A. Oosterhuis, and L.N. Went Ocular melanoma in families with dysplastic nevus syndrome J Am Acad Dermatol 23 1990 858 862 (Pubitemid 20366094)
82. A. Molven, M.B. Grimstvedt, S.J. Steine, M. Harland, M.F. Avril, and N.K. Hayward A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation Genes Chromosomes Cancer 44 2005 10 18 (Pubitemid 41060192)
83. M.R. Taylor, D. Guerry 4th, E.E. Bondi, J.A. Shields, J.J. Augsburger, and E.J. Lusk Lack of association between intraocular melanoma and cutaneous dysplastic nevi Am J Ophthalmol 98 1984 478 482 (Pubitemid 14021813)
84. S.W. Dusza, R. Delgado, K.J. Busam, A.A. Marghoob, and A.C. Halpern Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study J Drugs Dermatol 5 2006 56 62
85. N. Somani, M. Martinka, R.I. Crawford, J.P. Dutz, and J.K. Rivers Treatment of atypical nevi with imiquimod 5% cream Arch Dermatol 143 2007 379 385 (Pubitemid 46465709)
86. E.E. Bondi, W.H. Clark Jr., and D. Elder Guerry D 4th, Greene MH. Topical chemotherapy of dysplastic melanocytic nevi with 5% fluorouracil Arch Dermatol 117 1981 89 92 (Pubitemid 11138499)
87. J.J. Stam-Posthuma, J. Vink, S. le Cessie, J.A. Bruijn, W. Bergman, and S. Pavel Effect of topical tretinoin under occlusion on atypical naevi Melanoma Res 8 1998 539 548 (Pubitemid 29046505)
88. L. Edwards, F. Meyskens, and N. Levine Effect of oral isotretinoin on dysplastic nevi J Am Acad Dermatol 20 1989 257 260 (Pubitemid 19055634)
89. D. Duke, H.R. Byers, A.J. Sober, R.R. Anderson, and J.M. Grevelink Treatment of benign and atypical nevi with the normal-mode ruby laser and the Q-switched ruby laser: clinical improvement but failure to completely eliminate nevomelanocytes Arch Dermatol 135 1999 290 296 (Pubitemid 29159211)
90. A.J. Stratigos, J.S. Dover, and K.A. Arndt Laser treatment of pigmented lesions - 2000: how far have we gone? Arch Dermatol 136 2000 915 921 (Pubitemid 30604291)
91. C. Brod, W. Schippert, and H. Breuninger Dysplastic nevus syndrome with development of multiple melanomas. A surgical concept for prophylaxis J Dtsch Dermatol Ges 7 2009 773 775
92. K.L. Duffy, D.J. Mann, V. Petronic-Rosic, and C.R. Shea Clinical decision making based on histopathological grading and margin status of dysplastic nevi Arch Dermatol 148 2012 259 260
93. M.W. Piepkorn, R.L. Barnhill, L.A. Cannon-Albright, D.E. Elder, D.E. Goldgar, and C.M. Lewis A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi J Am Acad Dermatol 30 1994 707 714 (Pubitemid 24157110)
94. L. Brochez, E. Verhaeghe, E. Grosshans, E. Haneke, G. Piérard, and D. Ruiter Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions J Pathol 196 2002 459 466 (Pubitemid 34262859)
95. M. Shapiro, M.M. Chren, R.M. Levy, D.E. Elder, P.E. LeBoit, and M.C. Mihm Jr. Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists J Cutan Pathol 31 2004 523 530 (Pubitemid 39061800)
96. R. Kornberg, and A.B. Ackerman Pseudomelanoma: recurrent melanocytic nevus following partial surgical removal Arch Dermatol 111 1975 1588 1590
97. B. Bates With dysplastic nevi, pause before you biopsy Family Practice News October 15, 2006
98. R. King, B.A. Hayzen, R.N. Page, P.B. Googe, D. Zeagler, and M.C. Mihm Jr. Recurrent nevus phenomenon: a clinicopathologic study of 357 cases and histologic comparison with melanoma with regression Mod Pathol 22 2009 611 617
99. A.G. Goodson, S.R. Florell, K.M. Boucher, and D. Grossman Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi J Am Acad Dermatol 62 2010 591 596
100. A. Batistatou, A. Zioga, J. Panelos, D. Massi, N.J. Agnantis, and K. Charalabopoulos A new concept of melanocytic neoplasia pathogenesis based on the phenotype of common acquired nevi Med Hypotheses 69 2007 1334 1339 (Pubitemid 47633041)
101. T. Wiesner, A.C. Obenauf, R. Murali, I. Fried, K.G. Griewank, and P. Ulz Germline mutations in BAP1 predispose to melanocytic tumors Nat Genet 43 2011 1018 1021